


Reference Data

(Consolidated Financial Results for FY2010)



Daiichi-Sankyo

May 12, 2011

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

MEMO

(This page is intentionally left blank)

Contents

1.	Consolidated Income Statement	P1
2.	Currency Rate	P1
3.	Segment Information	P2
4.	Sales by Business Units	P3
5.	Sales of Global Products	P6
6.	Number of Employees	P7
7.	Management / Financial Indicators	P8
8.	Capital Expenditure and Depreciation Expenses	P8
9.	Consolidated Balance Sheets	P9
10.	Consolidated Statements of Cash Flow	P11
11.	R&D Pipeline	P13

Supplemental Information

Historical Data

Summary of Product Outlines

1. Summary of Consolidated Income Statement

JPY Bn	Q1			Q2			Q3			Q4			FY2010				FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY	to sales	Forecast	YoY	YoY
Net sales	100%	256.4	+12.9%	100%	242.5	-0.4%	100%	249.2	-2.3%	100%	219.3	-3.2%	100%	967.4	15.3	+1.6%	100%	970.0	2.6	+0.3%
Cost of sales	25%	64.1	+2.5%	31%	74.4	-0.4%	30%	74.6	-1.1%	31%	68.6	+5.0%	29%	281.7	3.6	+1.3%	30%	290.0	8.3	+3.0%
Gross Profit	75%	192.4	+16.9%	69%	168.0	-0.4%	70%	174.6	-2.8%	69%	150.7	-6.4%	71%	685.7	11.6	+1.7%	70%	680.0	-5.7	-0.8%
SG&A expenses	51%	131.3	-4.7%	57%	139.0	-3.9%	58%	144.1	+2.6%	68%	149.2	-4.1%	58%	563.5	-15.0	-2.6%	61%	590.0	26.5	+4.7%
R&D expenses	17%	43.6	-3.4%	19%	45.7	-6.7%	21%	53.0	+11.4%	24%	52.0	-5.6%	20%	194.3	-2.5	-1.3%	21%	200.0	5.7	+2.9%
Other expenses	34%	87.7	-5.4%	38%	93.3	-2.5%	37%	91.1	-2.0%	44%	97.2	-3.3%	38%	369.2	-12.5	-3.3%	40%	390.0	20.8	+5.6%
Operating Income	24%	61.1	+128.1%	12%	29.0	+20.6%	12%	30.5	-22.2%	1%	1.5	-72.2%	13%	122.1	26.6	+27.9%	9%	90.0	-32.1	-26.3%
Non-operating income / expenses		9.0			-6.5			7.4			-0.4			9.6	2.0			0.0	-9.6	
Non-operating income		11.8			-1.7			7.5			5.6			23.2	-5.0			not disclosed		
Non-operating expenses		2.8			4.8			0.0			6.0			13.6	-7.0			not disclosed		
Ordinary Income	27%	70.1	+877.7%	9%	22.6	-50.0%	15%	38.0	-1.1%	1%	1.2	-90.7%	14%	131.8	28.6	+27.8%	9%	90.0	-41.8	-31.7%
Extraordinary income / losses		-4.0			5.5			-1.2			-11.6			-11.3	-5.6			-4.0	7.3	
Extraordinary income		0.8			6.8			0.9			4.3			12.8	6.9			not disclosed		
Extraordinary losses		4.8			1.3			2.2			15.9			24.2	12.5			not disclosed		
Income before income taxes and minority interests	26%	66.1	+665.1%	12%	28.0	-37.7%	15%	36.7	-1.6%	-5%	-10.4	-	12%	120.4	23.0	+23.7%	9%	86.0	-34.4	-28.6%
Income taxes / minority interests		33.0			9.0			9.2			-0.9			50.3	-5.2			41.0	-9.3	
Income taxes		26.6			8.2			8.0			-0.9			41.8	-8.2			not disclosed		
Minority interests		6.5			0.8			1.2			0.0			8.5	3.0			not disclosed		
Net Income	13%	33.1	-	8%	19.1	-24.1%	11%	27.5	+33.8%	-4%	-9.5	-	7%	70.1	28.3	+67.5%	5%	45.0	-25.1	-35.8%
Effective tax rate		40%			29%			22%			-			35%						
Overseas sales ratio results		52%			51%			46%			53%			51%						

Notes to FY2010 Results Year-on-Year Comparisons

Net sales	Ranbaxy +25.4, Olmesartan +3.2, Prasugrel alliance revenue +4.7, Loxonin +7.2, Inavir +6.6, Denosumab milestone payment +5.5	
	Levofloxacin -18.1, Pravastatin -10.1, Return of sales rights -8.0	
	(appreciation of JPY to USD and EUR -29.0, Impact of NHI drug price cut in Japan -30.0)	
SG&A expenses	R&D: Forex impact -7.5, Decrease in co-development cost (denosumab), Esomeprazole in-licensese cost +8.2	
Non-operating items	Income: Decrease in forex derivative valuation gain of Ranbaxy	
Extraordinary items	Income: Increase in gain on sales of non-current assets / investment securities	
Income taxes	Improvement in effective tax rate (FY2009: amendment of income taxes for FY08, FY2010: Deferred tax accounting applied to loss carried forward taken over through Asubio reorganization)	
	Other: Forex Impact -16.0	Expenses: Decrease in forex losses of Ranbaxy
		Losses: Increase in impairment loss / loss on disaster

Notes to FY2011 Forecast

Net sales	Japan Company +19.0 (Olmesartan +23.0, Return of sales rights -24.0, new product launches), Overseas business +7.7	
	Levofloxacin export / royalties -21.1, Ranbaxy -9.9 (appreciation of JPY to INR -3.0, decrease in other operating income)	
	(appreciation / depreciation of JPY to USD and EUR -6.0)	
SG&A expenses	R&D: Progress in key R&D projects (+), Plexxikon (+), Esomeprazole in-license cost -8.2	
cost increase(+)/decrease(-)	Other: New product launches in Japan (+), Marketing efficiency optimization in US (-), Luitpold new product launch (+), Plexxikon (+)	
Extraordinary items	Losses: Fixed cost at manufacturing facility for the period when its operations are suspended, etc	
	[Reference] Impact (tentative) to operating income of the Plexxikon acquisition -4.0	

2. Currency Rate

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2010		FY2011
	Results	Results	Results	Results	Results	YoY	Forecast
USD/JPY (average)	92.02	88.95	86.53	85.72	85.72	-7.14	83.00
EUR/JPY (average)	117.00	113.84	113.31	113.13	113.13	-18.03	115.00
INR/JPY (average)	1.98	2.01	1.96	1.93	1.93	-0.02	1.90

Appreciation of JPY to USD and EUR negatively affected the FY2010 results by 29 bil yen in net sales and 4.5 bil yen in operating income, and is estimated to negatively affect FY2011 forecast by 6 bil yen in net sales.

Annual impact of one yen change is estimated to affect the group's FY2011 performance by: USD: net sales 2.4 bil yen, operating income minor / EUR: net sales 0.7 bil yen, operating income 0.1 bil yen

3. Segment Information

Daichi Sankyo Group	Q1			to sales	Q2			to sales	Q3			to sales	Q4			FY2010				
	to sales	Results	YoY		to sales	Results	YoY		to sales	Results	YoY		to sales	Results	YoY	to sales	Results	YoY	YoY	
Net sales	100%	201.6	+2.1%		100%	198.8	-4.0%		100%	213.7	-2.4%		100%	181.3	-0.3%		100%	795.5	-10.0	-1.2%
Cost of sales	22%	44.9	-1.1%		27%	54.4	+0.1%		26%	55.0	-1.1%		26%	47.6	+0.5%		25%	201.8	-0.8	-0.4%
Gross Profit	78%	156.7	+3.1%		73%	144.4	-5.4%		74%	158.8	-2.9%		74%	133.8	-0.6%		75%	593.7	-9.1	-1.5%
SG&A expenses	56%	113.5	-7.0%		61%	121.2	-4.2%		60%	127.7	+2.7%		73%	131.5	-2.5%		62%	493.9	-13.7	-2.7%
R&D expenses	20%	40.3	-6.2%		22%	43.5	-6.9%		24%	50.6	+12.0%		27%	49.6	-4.0%		23%	184.0	-2.5	-1.3%
Other expenses	36%	73.2	-7.4%		39%	77.7	-2.6%		36%	77.1	-2.6%		45%	81.9	-1.5%		39%	309.9	-11.2	-3.5%
Operating Income	22%	43.3	+44.0%		12%	23.2	-11.6%		15%	31.1	-20.6%		1%	2.3	-1422.3%		13%	99.8	4.6	+4.8%
Non-operating income		1.8				1.9				2.6				0.9				7.2	0.2	
Non-operating expenses		1.7				2.0				-0.1				3.4				7.0	0.9	
Ordinary Income	22%	43.4	+34.8%		12%	23.1	-12.6%		16%	33.7	-12.9%		0%	-0.2	-		13%	100.0	3.8	+4.0%
Extraordinary income		0.8				3.8				1.4				4.3				10.2	5.7	
Extraordinary losses		4.2				1.0				0.7				15.0				20.9	9.3	
Income before income taxes and minority interests	20%	40.0	+18.8%		13%	25.9	-1.6%		16%	34.4	-8.6%		-6%	-10.9	-		11%	89.3	0.2	+0.2%
Income taxes		17.7				7.5				8.5				-3.1				30.6	-23.7	
Minority interests																				
Net Income	11%	22.3	+122.8%		9%	18.3	+39.4%		12%	26.0	+30.0%		-4%	-7.8	-		7%	58.8	23.9	+68.6%

Ranbaxy Group																				
Net sales	100%	54.9	+84.9%		100%	43.8	+20.1%		100%	35.5	-1.4%		100%	38.9	-12.6%		100%	173.1	26.4	+18.0%
Cost of sales	35%	19.2	+12.0%		46%	20.0	-1.8%		55%	19.5	-1.7%		54%	21.0	+16.6%		46%	79.8	4.4	+5.8%
Gross Profit	65%	35.7	+184.1%		54%	23.7	+48.0%		45%	16.0	-1.1%		46%	17.9	-32.5%		54%	93.3	22.1	+31.0%
SG&A expenses	30%	16.4	+13.9%		39%	17.1	+2.9%		43%	15.4	+5.3%		43%	16.7	-13.5%		38%	65.6	0.7	+1.0%
R&D expenses	6%	3.3	+56.2%		7%	3.0	+32.0%		8%	2.8	+19.0%		7%	2.8	-19.0%		7%	12.0	1.7	+16.7%
Other expenses	24%	13.1	+6.7%		32%	14.1	-1.8%		35%	12.5	+2.6%		36%	13.9	-12.3%		31%	53.5	-1.1	-2.0%
Operating Income	35%	19.3	-1171.9%		15%	6.6	-1214.7%		2%	0.6	-60.0%		3%	1.1	-83.9%		16%	27.7	21.4	+338.8%
Non-operating income		10.0				-3.0				4.9				4.2				16.2	-5.0	
Non-operating expenses		1.1				2.7				0.1				0.1				3.9	-10.5	
Ordinary Income	52%	28.3	-220.1%		2%	0.9	-95.4%		16%	5.5	+374.9%		14%	5.3	-65.1%		23%	40.0	27.0	+207.8%
Extraordinary income		0.0				5.2				0.0				-0.1				5.1	3.8	
Extraordinary losses		0.7				0.1				1.5				6.0				8.3	8.2	
Income before income taxes and minority interests	50%	27.6	-217.5%		14%	6.0	-70.2%		11%	4.0	+249.7%		-2%	-0.8	-		21%	36.8	22.6	+158.6%
Income taxes		9.2				1.5				0.1				2.4				13.2	3.4	
Minority interests		0.1				0.1				0.1				0.1				0.3	0.1	
Net Income	33%	18.4	-		10%	4.5	-68.3%		11%	3.8	-		-9%	-3.3	-		14%	23.3	19.1	+456.4%

Inter-segment Transactions																				
Net sales		-0.1				-0.1				-0.1				-0.9				-1.2		
Cost of sales		0.0				0.0				0.1				0.0				0.1		
Gross Profit		-0.1				-0.1				-0.2				-0.9				-1.3		
SG&A expenses		1.5				0.7				1.0				1.0				4.1		
R&D expenses		0.0				-0.8				-0.4				-0.4				-1.7		
Other expenses		1.5				1.5				1.4				1.4				5.8		
Operating Income		-1.5				-0.7				-1.2				-1.9				-5.4		
Non-operating income		0.0				-0.7				-0.1				0.5				-0.2		
Non-operating expenses						0.1				0.0				2.5				2.6		
Ordinary Income		-1.5				-1.5				-1.3				-3.9				-8.2		
Extraordinary income		0.0				-2.2				-0.5				0.1				-2.5		
Extraordinary losses						0.2				0.0				-5.2				-5.0		
Income before income taxes and minority interests		-1.5				-3.9				-1.7				1.4				-5.7		
Income taxes		-0.3				-0.8				-0.6				-0.2				-2.0		
Minority interests		6.4				0.7				1.1				-0.1				8.2		
Net Income		-7.6				-3.8				-2.2				1.6				-12.0		

4. Sales by Business Units

	FY2010 Plan *2	Q1 Results YoY to plan			Q2 Results YoY to plan			Q3 Results YoY to plan			Q4 Results YoY to plan			FY2010 Results YoY to plan			FY2011 Plan YoY	
JPY Bn																		
Consolidated Net Sales	980.0	256.4	+12.9%	26%	242.5	-0.4%	25%	249.2	-2.3%	25%	219.3	-3.2%	22%	967.4	+1.6%	99%	970.0	+0.3%
Japan Company (domestic sales)	415.0	105.3	+0.6%	25%	103.0	-1.7%	25%	116.8	-1.4%	28%	91.0	+7.6%	22%	416.0	+0.9%	100%	435.0	+4.6%
Olmetec	86.0	20.7	+8.7%	24%	21.1	+6.5%	25%	23.0	+3.5%	27%	17.6	+8.5%	20%	82.3	+6.6%	96%	93.0	+13.0%
Rezaltas	5.0	1.8	-	36%	0.1	-	2%	1.3	-	27%	1.4	-	29%	4.7	-	93%	17.0	+264.3%
Calblock	14.0	3.7	+6.5%	26%	3.5	+0.6%	25%	3.8	-0.6%	27%	2.9	+1.3%	21%	14.0	+1.9%	100%	15.0	+7.5%
Loxonin	51.0	13.0	+15.9%	26%	13.9	+11.0%	27%	14.7	+10.0%	29%	12.6	+27.3%	25%	54.2	+15.3%	106%	58.0	+7.1%
Cravit	33.0	7.8	-18.3%	24%	7.5	-36.7%	23%	9.3	-14.5%	28%	7.8	-31.7%	24%	32.4	-25.8%	98%	38.0	+17.4%
Mevalotin	37.0	10.2	-17.9%	28%	10.1	-18.9%	27%	10.0	-22.0%	27%	7.8	-8.8%	21%	38.1	-17.6%	103%	32.0	-15.9%
Artist	22.5	6.1	+1.8%	27%	5.8	-1.6%	26%	6.3	-0.9%	28%	5.4	+8.5%	24%	23.7	+1.6%	105%	23.0	-3.0%
Omnipaque	23.0	6.4	-10.1%	28%	6.6	-12.4%	29%	6.5	-8.5%	28%	5.4	-0.2%	24%	25.0	-8.3%	109%	23.0	-8.0%
Urief	11.5	2.5	+11.2%	22%	2.5	+9.2%	21%	2.8	+9.2%	24%	2.3	+16.5%	20%	10.1	+11.3%	88%	11.0	+9.4%
Inavir	not disclosed	-	-	-	-	-	-	2.8	-	-	3.9	-	-	6.6	-	-	9.0	+35.6%
Vaccines	not disclosed	1.7	+36.2%	-	4.6	+139.8%	-	8.5	-1.2%	-	2.9	+128.3%	-	17.8	+35.6%	-	not disclosed	-
Daiichi Sankyo Espha products	not disclosed	-	-	-	-	-	-	2.6	-	-	2.0	-	-	4.6	-	-	not disclosed	-
Daiichi Sankyo Healthcare (OTC)	48.5	9.3	-2.7%	19%	11.7	-12.9%	24%	13.2	+9.1%	27%	10.6	+23.2%	22%	44.8	+2.6%	92%	49.0	+9.3%
Daiichi Sankyo, Inc. (US)	145.0	33.6	+1.7%	23%	33.9	+1.2%	23%	34.6	+0.6%	24%	28.4	-11.6%	20%	130.5	-1.9%	90%	130.0	-0.4%
Olmesartan	not disclosed	25.2	+0.6%	-	24.7	-2.5%	-	24.6	-6.9%	-	19.9	-19.8%	-	94.5	-7.1%	-	88.0	-6.8%
Benicar/Benicar HCT	89.5	21.4	-2.9%	24%	20.7	-6.8%	23%	20.6	-9.4%	23%	17.0	-22.5%	19%	79.7	-10.4%	89%	67.0	-15.9%
Azor	13.0	3.8	+25.8%	29%	3.4	+6.8%	26%	3.5	-5.3%	27%	2.6	-9.7%	20%	13.3	+4.1%	102%	13.5	+1.5%
Tribenzor	not disclosed	-	-	-	0.7	-	-	0.5	-	-	0.3	-	-	1.5	-	-	7.5	+415.9%
Welchol	28.5	7.0	+1.8%	25%	7.4	+13.4%	26%	7.9	+7.6%	28%	6.3	-8.3%	22%	28.5	+3.6%	100%	32.0	+12.2%
Effient (alliance revenue)	not disclosed	0.4	-	-	0.8	-	-	1.1	-	-	1.3	-	-	3.4	-	-	not disclosed	-
Luitpold Pharmaceuticals, Inc. (US)	47.0	14.7	+10.4%	31%	13.7	+1.3%	29%	11.5	-8.5%	24%	14.0	+10.5%	30%	53.9	+3.5%	115%	49.0	-9.1%
Venofer	27.0	8.4	+5.2%	31%	7.7	-5.0%	29%	5.8	-27.1%	22%	8.7	+8.4%	32%	30.7	-4.6%	114%	25.0	-18.5%
Daiichi Sankyo Europe GmbH	75.5	14.8	-14.6%	20%	16.6	-10.0%	22%	18.1	-5.0%	24%	16.9	-17.2%	22%	66.4	-11.7%	88%	77.0	+15.9%
Olmesartan	not disclosed	9.6	+4.5%	-	11.7	+4.5%	-	13.4	+7.9%	-	11.5	-14.7%	-	46.2	-0.2%	-	55.0	+19.1%
Olmetec/Olmetec Plus	41.0	7.9	-4.2%	19%	9.3	-6.7%	23%	10.1	-1.6%	25%	9.4	-17.9%	23%	36.7	-8.1%	90%	40.0	+9.0%
Sevikar	9.5	1.7	+84.9%	18%	2.4	+97.4%	25%	2.3	+5.7%	24%	2.0	-0.4%	22%	8.4	+32.5%	88%	12.0	+43.1%
Sevikar HCT	not disclosed	-	-	-	-	-	-	1.0	-	-	0.1	-	-	1.1	-	-	3.0	+172.3%
*1 Effient (alliance revenue)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	not disclosed	-

	FY2010 Plan *2	Q1 Results YoY to plan	Q2 Results YoY to plan	Q3 Results YoY to plan	Q4 Results YoY to plan	FY2010 Results YoY to plan	FY2011 Plan YoY
Asia, South and Central America (ASCA)	28.0	5.9 +12.7% 21%	7.1 +12.8% 25%	6.8 +3.3% 24%	7.6 -0.4% 27%	27.4 +6.4% 98%	30.0 +9.3%
Daiichi Sankyo Pharmaceutical (Beijing)	3.9	1.1 +17.8% 29%	1.1 +3.6% 29%	1.1 -6.3% 28%	0.9 -2.2% 23%	4.2 +2.9% 108%	not disclosed -
Daiichi Sankyo Pharmaceutical (Shanghai)	6.7	1.4 +35.5% 21%	1.7 +32.5% 26%	1.6 +10.5% 24%	1.8 +20.7% 27%	6.6 +23.8% 98%	not disclosed -
Daiichi Sankyo Taiwan	3.1	0.8 -8.6% 26%	0.8 +1.0% 26%	0.8 +13.5% 25%	1.0 +29.2% 31%	3.4 +7.9% 109%	not disclosed -
Daiichi Sankyo Korea	4.7	1.0 +31.4% 21%	0.9 +2.9% 19%	1.0 +9.7% 21%	1.1 +29.6% 24%	4.0 +17.9% 85%	not disclosed -
Daiichi Sankyo (Thailand)	1.4	0.2 +35.8% 17%	0.3 +22.8% 22%	0.3 +53.4% 23%	0.3 +26.9% 25%	1.2 +33.8% 86%	not disclosed -
Daiichi Sankyo Brasil Farmacêutica	5.6	1.0 +36.5% 18%	1.4 +39.5% 26%	1.4 +6.4% 25%	1.3 -19.9% 23%	5.2 +9.5% 92%	not disclosed -
Daiichi Sankyo Venezuela	2.9	0.4 -46.7% 13%	0.7 -18.7% 25%	0.6 -25.1% 22%	1.1 -32.7% 40%	2.9 -30.5% 100%	not disclosed -
Ranbaxy Laboratories Limited	165.0	54.8 +84.7% 33%	43.7 +19.9% 27%	35.4 -1.6% 22%	38.0 -14.5% 23%	171.9 +17.3% 104%	162.0 -5.8%
Others	56.0	18.0 +25.6% -	12.8 -25.1% -	12.7 -20.2% -	12.8 -20.0% -	56.3 -11.1% -	38.0 -32.5%
Levofloxacin export, royalty, etc	28.5	7.1 -16.2% 25%	7.2 -25.3% 25%	6.6 -27.5% 23%	7.2 -16.8% 25%	28.1 -21.7% 99%	7.0 -75.1%
*1 Efient alliance revenue (Europe)	not disclosed	0.4 - -	0.2 - -	0.4 +278.5% -	0.7 +97.7% -	1.8 +285.9% -	- -

Currency rates for overseas subsidiaries

	Plan	Q1 Results	Q2 YTD Results	Q3 YTD results	Q4 YTD Results	FY2010 Results	FY2011 Plan
USD/JPY (average)	90.00	92.02	88.95	86.53	85.72	85.72	83.00
EUR/JPY (average)	120.00	117.00	113.84	113.31	113.13	113.13	115.00
INR/JPY (average)	2.10	1.98	2.01	1.96	1.93	1.93	1.90

New Product Launches

Apr 2010: Rezaltas (anti-hypertensive) launched in Japan

Aug 2010: Tribenzor (anti-hypertensive) launched in the US

Oct 2010: Loxonin Gel (percutaneous analgesic and anti-inflammatory drug) launched in Japan. Sales of Loxonin Gel are included in Loxonin.

Oct 2010: Inavir (anti-influenza) launched in Japan

Dec 2010: Sevikar HCT (anti-hypertensive) launched in Europe

Jan 2011: Cravit Intravenous Injections (anti-bacterial) launched in Japan. Sales of Cravit Intravenous Injections are included in Cravit.

Notes

*1 Alliance revenue of Efient (Europe) will be included in Daiichi Sankyo Europe GmbH from FY2011

*2 2010 Plan are those announced at the beginning of the fiscal year (May 2010)

[Reference] Sales in Local Currency

	FY2010 Plan	Q1 Results YoY to plan			Q2 Results YoY to plan			Q3 Results YoY to plan			Q4 Results YoY to plan			FY2010 Results YoY to plan			FY2011 Plan YoY	
USD Mn																		
Daiichi Sankyo, Inc. (US)	1,611	365	+7.6%	23%	394	+10.2%	24%	422	+10.3%	26%	342	-3.3%	21%	1,522	+6.3%	95%	1,566	+2.9%
Olmesartan	not disclosed	274	+6.4%	-	287	+6.2%	-	300	+2.3%	-	241	-12.2%	-	1,102	+0.6%	-	1,060	-3.8%
Benicar/Benicar HCT	994	233	+2.7%	23%	241	+1.6%	24%	251	-0.5%	25%	205	-15.2%	21%	930	-2.9%	94%	807	-13.2%
Azor	144	42	+33.1%	29%	39	+16.9%	27%	42	+4.6%	29%	32	-1.0%	22%	155	+12.7%	107%	163	+4.8%
Tribenzor	not disclosed	-	-	-	7	-	-	6	-	-	4	-	-	17	-	-	90	+432.8%
Welchol	317	76	+7.6%	24%	85	+23.1%	27%	95	+17.8%	30%	76	+0.3%	24%	333	+12.2%	105%	386	+15.9%
Effient (alliance revenue)	not disclosed	4	-	-	9	-	-	13	-	-	15	-	-	40	-	-	not disclosed	-
USD Mn																		
Luitpold Pharmaceuticals, Inc. (US)	522	160	+16.7%	31%	159	+10.6%	31%	142	+1.2%	27%	168	+20.1%	32%	629	+12.1%	120%	590	-6.1%
Venofer	300	92	+11.3%	31%	90	+3.8%	30%	72	-18.5%	24%	104	+17.5%	35%	358	+3.4%	119%	301	-15.8%
EUR Mn																		
Daiichi Sankyo Europe GmbH	629	126	-3.2%	20%	149	+8.3%	24%	161	+12.1%	26%	150	-7.0%	24%	587	+2.3%	93%	670	+14.1%
Olmesartan	not disclosed	82	+18.4%	-	105	+25.4%	-	119	+27.3%	-	102	-3.9%	-	408	+15.7%	-	478	+17.2%
Olmetec/Olmetec Plus	342	68	+8.5%	20%	83	+12.0%	24%	90	+16.1%	26%	83	-7.6%	24%	324	+6.5%	95%	348	+7.3%
Sevikar	79	14	+109.5%	18%	21	+136.0%	27%	20	+24.9%	26%	18	+12.8%	23%	74	+53.6%	94%	104	+40.8%
Sevikar HCT	not disclosed	-	-	-	-	-	-	9	-	-	1	-	-	10	-	-	26	+167.9%
*1 Effient (alliance revenue)	not disclosed	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	not disclosed	-
INR Bn																		
Ranbaxy Laboratories Limited	78	28	+76.3%	36%	21	+17.1%	27%	19	+4.6%	25%	21	-9.0%	27%	89	+18.5%	114%	85	-4.6%

5. Sales of Global Products

	FY2010 Plan	Q1			Q2			Q3			Q4			FY2010			FY2011	
		Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Plan	YoY
JPY Bn																		
Olmesartan	260.0	60.2	+7.6%	23%	61.4	+3.4%	24%	65.7	+1.6%	25%	54.2	-7.0%	21%	241.5	+1.4%	93%	270.0	+11.8%
Olmetec (JPN)	86.0	20.7	+8.7%	24%	21.1	+6.5%	25%	23.0	+3.5%	27%	17.6	+8.5%	20%	82.3	+6.6%	96%	93.0	+13.0%
Rezaltas (JPN)	5.0	1.8	-	36%	0.1	-	2%	1.3	-	27%	1.4	-	29%	4.7	-	93%	17.0	+264.3%
Benicar/Benicar HCT (US)	89.5	21.4	-2.9%	24%	20.7	-6.8%	23%	20.6	-9.4%	23%	17.0	-22.5%	19%	79.7	-10.4%	89%	67.0	-15.9%
Azor (US)	13.0	3.8	+25.8%	29%	3.4	+6.8%	26%	3.5	-5.3%	27%	2.6	-9.7%	20%	13.3	+4.1%	102%	13.5	+1.5%
Tribenzor (US)	not disclosed	-	-	-	-	-	-	0.5	-	-	0.3	-	-	1.5	-	-	7.5	+415.9%
Olmetec/Olmetec Plus (EU)	41.0	7.9	-4.2%	19%	9.3	-6.7%	23%	10.1	-1.6%	25%	9.4	-17.9%	23%	36.7	-8.1%	90%	40.0	+9.0%
Sevikar (EU)	9.5	1.7	+84.9%	18%	2.4	+97.4%	25%	2.3	+5.7%	24%	2.0	-0.4%	22%	8.4	+32.5%	88%	12.0	+43.1%
Sevikar HCT (EU)	not disclosed	-	-	-	-	-	-	1.0	-	-	0.1	-	-	1.1	-	-	3.0	+172.3%
Other subsidiaries, export, etc	16.0	2.8	+7.7%	18%	3.9	+25.4%	24%	3.5	-6.2%	22%	3.8	+0.8%	24%	13.9	+6.0%	87%	17.0	+22.0%
Levofloxacin	70.0	17.0	-14.3%	24%	16.9	-28.0%	24%	18.1	-18.3%	26%	17.2	-21.1%	25%	69.1	-20.7%	99%	53.0	-23.3%
Cravit (JPN)	33.0	7.8	-18.3%	24%	7.5	-36.7%	23%	9.3	-14.5%	28%	7.8	-31.7%	24%	32.4	-25.8%	98%	38.0	+17.4%
Export, royalty, etc	28.5	7.1	-16.2%	25%	7.2	-25.3%	25%	6.6	-27.5%	23%	7.2	-16.8%	25%	28.1	-21.7%	99%	7.0	-75.1%
Other subsidiaries	8.5	2.1	+15.8%	25%	2.2	+10.6%	26%	2.1	+2.0%	25%	2.2	+25.6%	26%	8.7	+12.9%	102%	8.0	-7.7%
Pravastatin	44.0	11.9	-19.1%	27%	11.8	-21.5%	27%	11.6	-21.8%	26%	9.6	-8.3%	22%	44.9	-18.4%	102%	38.0	-15.3%
Mevalotin (JPN)	37.0	10.2	-17.9%	28%	10.1	-18.9%	27%	10.0	-22.0%	27%	7.8	-8.8%	21%	38.1	-17.6%	103%	32.0	-15.9%
Other subsidiaries, export, etc	7.0	1.7	-25.8%	24%	1.7	-34.1%	25%	1.6	-20.9%	22%	1.8	-6.1%	26%	6.8	-22.8%	97%	6.0	-11.9%
Prasugrel (alliance revenue)	not disclosed	0.8	-	-	1.0	-	-	1.5	-	-	2.0	-	-	5.2	+889.6%	-	not disclosed	-
Effient alliance revenue (US)	not disclosed	0.4	-	-	0.8	-	-	1.1	-	-	1.3	-	-	3.4	-	-	not disclosed	-
Efient alliance revenue (EU)	not disclosed	0.4	-	-	0.2	-	-	0.4	+278.5%	-	0.7	+97.7%	-	1.8	+285.9%	-	not disclosed	-

6. Number of Employees

	Mar 2010 Result	Jun 2010 Result	Sep 2010 Result	Dec 2010 Result	Mar 2011 Result
Total Number of Employees	29,825	30,194	30,424	30,633	30,488
Japan	8,892	9,061	9,048	9,071	9,002
* Overseas	20,933	21,133	21,376	21,562	21,486
Daiichi Sankyo Group	16,830	17,037	17,019	17,275	17,065
* Ranbaxy Group	12,995	13,157	13,405	13,358	13,423

* For overseas subsidiaries with different fiscal year-ends, numbers as of Dec-end are shown in the Mar-end columns

7. Management / Financial Indicators

	FY2009 Q2 YTD Results	FY2009 Results	FY2010 Q2 YTD Results	FY2010 Results	FY2011 Forecast
Management Indicators					
Earnings per share (EPS)	26.6 Yen	59.5 Yen	74.1 Yen	99.6 Yen	63.9 Yen
Dividend per share	30.0 Yen	60.0 Yen	30.0 Yen	60.0 Yen	60.0 Yen
Dividend payout ratio (Consolidated)	113.0 %	100.9 %	40.5 %	60.2 %	93.9 %
Return on equity (ROE)	- %	4.9 %	- %	8.2 %	
Dividend on equity (DOE)	- %	4.9 %	- %	5.0 %	
Book value per share (BPS)	1,213.8 Yen	1,215.6 Yen	1,212.7 Yen	1,206.1 Yen	
Equity ratio	58.5 %	57.4 %	58.3 %	57.4 %	
Number of treasury stock purchased	-	-	-	-	
Total number of common shares	704 million	704 million	704 million	704 million	
Share price at end of period	1,853 Yen	1,751 Yen	1,698 Yen	1,606 Yen	
Market value	1,304.4 JPY Bn	1,232.6 JPY Bn	1,195.3 JPY Bn	1,130.4 JPY Bn	
Financial Indicators					
Total assets	1,460.3 JPY Bn	1,489.5 JPY Bn	1,465.0 JPY Bn	1,480.2 JPY Bn	
Current assets	771.5 JPY Bn	819.8 JPY Bn	843.6 JPY Bn	894.1 JPY Bn	
*1 Liquidity on hand	341.2 JPY Bn	358.3 JPY Bn	401.0 JPY Bn	426.8 JPY Bn	
Debt with interest	318.5 JPY Bn	290.9 JPY Bn	299.4 JPY Bn	299.4 JPY Bn	
Equity capital	854.4 JPY Bn	855.7 JPY Bn	853.6 JPY Bn	849.0 JPY Bn	
Cash flow from operating activities	39.6 JPY Bn	130.2 JPY Bn	77.3 JPY Bn	141.1 JPY Bn	
Cash flow from investing activities	54.9 JPY Bn	42.6 JPY Bn	-25.2 JPY Bn	-63.0 JPY Bn	
Cash flow from financial activities	-42.0 JPY Bn	-89.1 JPY Bn	-10.8 JPY Bn	-26.0 JPY Bn	
*2 Free cash flow	94.5 JPY Bn	172.9 JPY Bn	52.1 JPY Bn	78.2 JPY Bn	
Cash and cash equivalents, end of year	227.6 JPY Bn	259.2 JPY Bn	291.0 JPY Bn	302.4 JPY Bn	
Others					
Number of consolidated subsidiaries	96	99	98	101	

*1 Current deposits + marketable securities + investment securities, etc

2 Cash flow from operating activities and investing activities

8. Capital Expenditure and Depreciation and Amortization Expenses

	FY2009 Q2 YTD Results	FY2009 Results	FY2010 Q2 YTD Results	FY2010 Results	FY2011 Plan
Capital expenditure	12.7 JPY Bn	29.7 JPY Bn	15.3 JPY Bn	37.3 JPY Bn	50.0 JPY Bn
Depreciation and amortization expense	22.0 JPY Bn	45.9 JPY Bn	21.3 JPY Bn	43.9 JPY Bn	46.0 JPY Bn
Tangible assets	13.9 JPY Bn	28.8 JPY Bn	12.9 JPY Bn	27.5 JPY Bn	
Intangible assets	8.2 JPY Bn	17.1 JPY Bn	8.4 JPY Bn	16.5 JPY Bn	

9. Consolidated Balance Sheets

(Millions of yen*)

	Mar 2010	Mar 2011	YoY	Notes
ASSETS				
Current assets				
Cash and time deposits	100,996	262,037	161,041	Funding for acquisition of Plexxikon (Apr 2011)
Trade notes and accounts receivable	211,889	205,590	-6,299	
Marketable securities	236,541	157,653	-78,888	Funding for acquisition of Plexxikon (Apr 2011)
Merchandise and finished goods	91,708	89,143	-2,565	
Work in process	16,783	21,598	4,815	
Raw materials and supplies	34,733	32,050	-2,683	
Deferred tax assets	86,970	90,245	3,275	
Other current assets	41,802	38,075	-3,727	
Allowance for doubtful accounts	-1,668	-2,319	-651	
Total current assets	819,757	894,075	74,318	
Non-current assets				
Property, plant and equipment				
Buildings and structures, net	126,589	119,962	-6,627	
Machinery, equipment and vehicles, net	44,538	46,706	2,168	
Land	42,618	38,407	-4,211	
Construction in progress	22,294	20,599	-1,695	
Other, net	13,504	12,034	-1,470	
Net property, plant and equipment	249,546	237,710	-11,836	Transfer of Shizuoka factory, foreign exchange loss, etc.
Intangible assets				
Goodwill, net	73,769	67,316	-6,453	U3 Pharma -5.0 Bn, Ranbaxy -2.4 Bn
Other intangible assets, net	107,117	89,606	-17,511	Impairment loss -5.2 Bn, foreign exchange loss, etc
Total intangible assets	180,887	156,923	-23,964	
Investments and other assets				
Investment securities	137,042	102,416	-34,626	Valuation difference -16.2 Bn, Funding for redemption of Ranbaxy's convertible bonds
Prepaid pension costs	3,889	939	-2,950	
Deferred tax assets	81,758	73,245	-8,513	
Other	16,931	15,210	-1,721	
Allowance for doubtful accounts	-304	-281	23	
Total investments and other assets	239,318	191,531	-47,787	
Total non-current assets	669,752	586,164	-83,588	
Total assets	1,489,510	1,480,240	-9,270	

* All amounts have been rounded down to the nearest million yen

(Millions of yen*)

	Mar 2010	Mar 2011	YoY	Notes
LIABILITIES				
Current liabilities				
Trade notes and accounts payable	66,539	58,407	-8,132	
Current portion of convertible bond-type bonds with subscription rights to shares	—	46,020	46,020	Change from long-term financing
Short-term bank loans	19,988	29,342	9,354	Funding for redemption of Ranbaxy's convertible bonds, etc.
Income taxes payable	10,643	7,545	-3,098	
Allowance for sales returns	583	1,244	661	
Allowance for sales rebates	1,406	1,623	217	
Allowance for contingent losses	1,600	—	-1,600	
Provision for loss on disaster	—	4,570	4,570	
Asset retirement obligations	—	178	178	
Other current liabilities	168,050	158,019	-10,031	Decrease in Ranbaxy's payable towards unrealized loss on currency options, etc
Total current liabilities	268,812	306,952	38,140	
Long-term liabilities				
Bonds payable	100,000	100,000	—	
Convertible bond-type bonds with subscription rights to shares	49,534	—	-49,534	Change to short-term financing
Long-term debt	121,389	124,036	2,647	
Deferred tax liabilities	29,237	28,463	-774	
Accrued employees' severance and retirement benefits	12,320	11,541	-779	
Accrued directors' severance and retirement benefits	132	155	23	
Other long-term liabilities	18,574	21,388	2,814	
Total long-term liabilities	331,189	285,585	-45,604	
Total liabilities	600,001	592,537	-7,464	
NET ASSETS				
Shareholders' equity				
Common stock	50,000	50,000	—	
Capital surplus	105,194	105,194	—	
Retained earnings	746,392	774,274	27,882	Net income +70.1 Bn, Dividend paid -42.2 Bn
Treasury stock, at cost	-14,566	-14,581	-15	
Total shareholders' equity	887,020	914,888	27,868	
Accumulated other comprehensive income				
Net unrealized gain on investment securities	27,461	16,559	-10,902	
Deferred gains or losses on hedges	1,002	1,193	191	
Foreign currency translation adjustments	-59,778	-83,636	-23,858	
Total accumulated other comprehensive income	-31,314	-65,883	-34,569	
Subscription rights to shares	3,295	3,544	249	
Minority interests	30,506	35,153	4,647	
Total net assets	889,508	887,702	-1,806	
Total liabilities and net assets	1,489,510	1,480,240	-9,270	

* All amounts have been rounded down to the nearest million yen

10. Consolidated Statements of Cash Flows

(Millions of yen*)

	FY2009 Results	FY2010 Results	YoY	Notes
Cash flows from operating activities				
Income before income taxes and minority interests	97,371	120,419	23,048	
Depreciation	45,942	43,945	△1,997	
Loss on impairment of long-lived assets	2,103	6,451	4,348	FY2010: Intangible assets 5.2 Bn
Non-recurring depreciation on non-current assets	261	2,121	1,860	FY2010: Fukuroi Research Center
Amortization of goodwill	8,882	9,148	266	
(Gain) loss on valuation of derivatives	-17,155	-11,160	5,995	
Increase (decrease) in allowance for doubtful accounts	600	837	237	
Increase (decrease) in accrued severance and retirement benefits	1,436	558	△878	
(Increase) decrease in prepaid pension costs	3,031	2,297	△734	
Interest and dividend income	-6,190	-6,775	△585	
Interest expense	5,719	5,519	△200	
Foreign exchange (gains) losses	-2,636	-35	2,601	
Loss (gain) on valuation of investment securities	—	3,550	3,550	
(Gain) loss on sales of investment securities	-1,873	-2,932	△1,059	
(Gain) loss on sales of investments in affiliates	-1,060	-814	246	
(Gain) loss on sales and disposal of property, plant and equipment	-1,292	-6,066	△4,774	
Equity in net (income) losses of affiliated companies	175	2,645	2,470	
(Increase) decrease in trade notes and accounts receivable	-15,356	-1,436	13,920	
(Increase) decrease in inventories	-2,806	-7,144	△4,338	
Increase (decrease) in trade notes and accounts payable	6,436	-5,045	△11,481	
Increase (decrease) in accounts payable and accrued expenses	6,236	8,921	2,685	
Other, net	27,204	8,301	△18,903	FY2009: Refund of income taxes paid in FY2008
Subtotal	157,031	173,306	16,275	
Interest and dividends received	7,261	5,465	△1,796	
Interest paid	-3,644	-2,893	751	
Income taxes paid	-30,413	-34,738	△4,325	
Net cash provided by operating activities	130,235	141,139	10,904	

* All amounts have been rounded down to the nearest million yen

(Millions of yen*)

	FY2009 Results	FY2010 Results	YoY	Notes
Cash flows from investing activities				
Payments into time deposits	-31,357	-78,456	△47,099	
Proceeds from maturities in time deposits	36,189	48,473	12,284	
Purchases of marketable securities	-51,007	-134,752	△83,745	
Proceeds from sales of marketable securities	128,825	124,587	△4,238	
Acquisitions of property, plant and equipment	-28,870	-32,250	△3,380	
Proceeds from sales of property, plant and equipment	4,562	10,082	5,520	
Acquisitions of intangible assets	-2,287	-3,882	△1,595	
Acquisitions of investment securities	-6,747	-1,024	5,723	
Proceeds from sales of investment securities	6,607	8,790	2,183	
Acquisition of investments in subsidiaries	-1,498	-1,919	△421	FY2009: Ranbaxy's subsidiary in South Africa, FY2010: Zenotech
Purchase of investments in subsidiaries resulting in change in scope of consolidation	-14,446	-8,254	6,192	FY2009: PharmaForce, FY2010: Roxro
Proceeds from sales of investments in consolidated subsidiaries resulting in changes in scope of consolidation	2,975	5,641	2,666	FY2010: Transfer of Shizuoka factory
Net (increase) decrease in short-term loans receivable	-99	1,858	1,957	
Payment for loans receivable	-428	-27	401	
Proceeds from collection of loans receivable	39	0	△39	
Other, net	169	-1,832	△2,001	
Net cash provided by (used in) investing activities	42,627	-62,965	△105,592	
Cash flows from financing activities				
Net increase (decrease) in short-term bank loans	-246,772	13,755	260,527	
Proceeds from long-term debt	111,832	7,204	△104,628	
Repayments of long-term debt	-4,411	-4,806	△395	
Proceeds from issuance of bonds	99,688	—	△99,688	
Purchases of treasury stock	-28	-34	△6	
Proceeds from sale of treasury stock	5	2	△3	
Dividends paid	-49,256	-42,246	7,010	
Other, net	-178	144	322	
Net cash used in financing activities	-89,121	-25,979	63,142	
Effect of exchange rate changes on cash and cash equivalents	-2,296	-9,007	△6,711	
Net increase (decrease) in cash and cash equivalents	81,445	43,187	△38,258	
Cash and cash equivalents, beginning of year	177,769	259,215	81,446	
Cash and cash equivalents, at end of year	259,215	302,402	43,187	

* All amounts have been rounded down to the nearest million yen

11. Major R&D Pipeline

May 2011

Therapeutic Area	Phase1	Phase2	Phase3	Application
Cardiovascular- Metabolics	<p>CS-3150 (Antihypertensive)</p> <p>DS-7309 (Anti-diabetes)</p>	<p>DU-176b (US/EU) (Edoxaban / post surgical VTE / oral factor Xa inhibitor)</p> <p>CS-747 (JP) (Prasugrel / ischemic stroke / anti-platelet agent)</p> <p>CS-1036 (JP/Asia) (Glucose absorption inhibitor)</p>	<p>DU-176b (US/EU/JP/Asia) (Edoxaban / AF / oral factor Xa inhibitor)</p> <p>DU-176b (US/EU/JP/Asia) (Edoxaban / VTE / oral factor Xa inhibitor)</p> <p>★CS-747 (US/EU/Asia) (Prasugrel / ACS-MM / anti-platelet agent)</p> <p>CS-747 (JP) (Prasugrel / ACS-PCI / anti-platelet agent)</p>	<p>DU-176b (JP) (Edoxaban / post surgical VTE / oral factor Xa inhibitor)</p>
Oncology	<p>CS-7017 (JP/Asia) (Efatazone / PPARγ agonist)</p> <p>U3-1565 (US) (Anti-HB-EGF antibody)</p> <p>U3-1287 (JP) (Anti-HER3 antibody)</p> <p>DS-2248 (US) (Hsp90 inhibitor)</p>	<p>U3-1287 (US/EU) (Anti-HER3 antibody)</p> <p>CS-1008 (US/EU/JP/Asia) (Tigatuzumab / anti-DR5 antibody)</p> <p>CS-7017 (US/EU) (Efatazone / PPARγ agonist)</p> <p>DE-766 (JP) (Nimotuzumab / anti-EGFR antibody)</p> <p>PLX3397 (US) (Fms/Kit/Flt3-ITD inhibitor)</p>	<p>ARO 197 (US/EU) (Tivantinib / NSCLC / c-Met inhibitor)</p>	<p>PLX4032 (US/EU) (Vemurafenib / Melanoma / BRAF inhibitor)</p>
Infectious diseases	<p>CS-8958 (US/EU) (Laninamivir / anti-influenza / co-development with Biota)</p> <p>CS-4771 (Anti-Sepsis)</p> <p>DS-8587 (Broad spectrum antibacterial agent)</p>		<p>★CS-8958 (JP) (Laninamivir / anti-influenza, prophylactic / Neuraminidase inhibitor)</p>	
Bone/Joint diseases	<p>PLX5622 (Rheumatoid arthritis)</p>	<p>AMG 162 (JP) (Denosumab / rheumatoid arthritis / anti-RANKL antibody)</p>	<p>AMG 162 (JP) (Denosumab / osteoporosis, breast cancer adjuvant / anti-RANKL antibody)</p>	<p>AMG 162 (JP) (Denosumab / bone metastases of cancer/ anti-RANKL antibody)</p>
Immunological allergic diseases	<p>CS-0777 (Immunomodulator)</p>	<p>SUN13834 (US) (Chymase inhibitor)</p>		
Others	<p>DS-5565 (Chronic pain)</p> <p>SUN13837 (Spinal cord injury)</p>	<p>SUN11031 (US/EU) (Human ghrelin / COPD cachexia)</p>	<p>SUN11031 (JP) (Human ghrelin / anorexia nervosa)</p> <p>★DD-723-B (JP) (Perflubutane / Contrast agents in ultrasound for prostate cancer and breast tumor/ ultrasound contrast agent)</p>	<p>KMD-3213 (China) (Sildenafil / treatment of dysuria associated with benign prostatic hyperplasia/ Selective alpha 1A blocker)</p>

★Additional indications, new formulations etc.

Change from the announcement in January 2011

New (underline)

PLX4032 (Melanoma/BRAF inhibitor/US/EU/Application)

PLX3397 (Fms/Kit/Flt3-ITD inhibitor/US/P2)

PLX5622 (Rheumatoid arthritis/P1)

DS-7309 (Anti-diabetes/P1)

DS-2248 (Hsp90 inhibitor/P1)

SUN13837 (Spinal cord injury/P1)

Change of Stage

DU-176b (Post surgical VTE/oral factor Xa inhibitor/JP/Approved)

Discontinued etc.

CS-1036 (Glucose absorption inhibitor/JP/Asia/P2)

Cardiovascular-Metabolics

[project after Phase II]

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
DU-176b	edoxaban	Oral	Factor Xa inhibitor	1) Atrial fibrillation (AF) 2) Venous thromboembolism (VTE) 3) Post surgical VTE	Daiichi Sankyo	US/EU JP Asia	1)P3, 2)P3, 3) P2 1)P3, 2)P3, 3) Approved 1)P3, 2)P3, 3) -
<ul style="list-style-type: none"> An oral anticoagulant that specifically, reversibly and directly inhibits Xa factor playing an important role in the process when blood coagulates. An oral factor Xa inhibitor, possible once daily regimen with high oral absorption, confirmed by clinical trials. No severe hepatotoxicity signals in pre-clinical and clinical trials Development by Daiichi Sankyo globally <ul style="list-style-type: none"> A P3 multi-national trial in AF, completed its patient enrollment in Nov-2010. (ENGAGE AF-TIMI48) A P3 multi-national trial for prevention of recurrent VTE in patients with deep-vein thrombosis and/or pulmonary embolism started in Jan-2010.(HOKUSAI VTE) [JP] Approved for the prevention of VTE after major orthopedic surgery in April-2011. Brand name: Lixiana 							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-747	prasugrel	Oral	Anti-platelet agent	1) Acute coronary syndrome(ACS-PCI) 2) Acute coronary syndrome(ACS-MM) 3) Ischemic stroke	Daiichi Sankyo Ube Industries	US/EU/Asia JP	1) Approved, 2)P3, 3)- 1) P3, 2) -, 3)P2
<ul style="list-style-type: none"> Inhibition platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate(ADP) receptor on the platelet surface. Co-development with Eli Lilly in the US and EU, development by Daiichi Sankyo in Japan In June, 2008, a new P3 trial (TRILOGY ACS) started in US and EU for patients with acute coronary syndrome, not being managed with percutaneous coronary intervention (ACS-MM). [EU] Approved in Feb-2009 for ACS-PCI. Brand name: Effient [US] Approved in Jul-2009 for ACS-PCI. Brand name: Effient [JP] A P3 study for ACS-PCI is on-going. P3 studies for elective PCI and ischemic stroke are in preparation. 							

Oncology

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
ARQ 197	tivantinib	Oral	c-Met inhibitor	-	ArQule	US/EU	P3
<ul style="list-style-type: none"> c-Met has multiple roles in intracellular signal transductions such as cancer cell motility, proliferation, angiogenesis, invasion, and apoptosis induction. Variations of c-Met are shown in gastric, HCC, head and neck cancer, and high expression of c-met are shown in colon, HCC, pancreatic, prostate, breast cancer, etc. Clinical studies are on-going for several types of cancer. A P3 clinical trial for NSCLC is on-going. 							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-1008	tigatuzumab	Injection	Anti-DR5 antibody	-	Daiichi Sankyo	US/EU JP/Asia	P2
<ul style="list-style-type: none"> A humanized version TRA-8, a murine agonistic Mab raised against human death receptor 5(DR5). DR5 is rarely expressed in normal tissues, expected to show selective activity against tumor cells. Induces apoptosis of tumor cells expressing DR5 on the cell surface. Clinical studies are on-going for several types of cancer. 							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
DE-766	nimotuzumab	Injection	Anti-EGFR antibody	-	CIMYM Biosciences	JP	P2
<ul style="list-style-type: none"> • A humanized monoclonal antibody against Epidermal Growth Factor Receptor(EGFR). • Expected to be a best in class EGFR antibody, safety against the skin toxicity and the efficacy comparable to the other EGFR antibodies. • Clinical studies are on-going for several types of cancer. 							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-7017	efatutazone	Oral	PPAR-gamma agonist	-	Daiichi Sankyo	US/EU JP/Asia	P2 P1
<ul style="list-style-type: none"> • Inhibits growth of tumor cells in vitro without killing those cells. • Expected to be less toxic compared to standard chemotherapeutics. • Clinical studies are on-going for several types of cancer. 							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
U3-1287	-	Injection	Anti-HER3 antibody	-	Daiichi Sankyo (U3 Pharma)	US/EU JP	P2 P1
<ul style="list-style-type: none"> • HER3 is one of the member of the Epidermal Growth Factor Receptor(EGFR) family of proteins. • HER3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are more potent to induce cell proliferation than homodimers of HER2 or EGFR • Clinical studies are on-going for several types of cancer. 							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
PLX4032	vemurafenib	Oral	BRAF inhibitor	-	Daiichi Sankyo (Plexxikon Inc.)	US/EU	Application
<ul style="list-style-type: none"> • Plexxikon discovered vemurafenib and co-developed it with Genentech/Roche. • Filed for the treatment of metastatic melanoma with the BRAF mutation in US and EU. 							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
PLX3397	-	Oral	Fms/Kit/Flt3-ITD inhibitor	-	Daiichi Sankyo (Plexxikon Inc.)	US	P2
<ul style="list-style-type: none"> • A P2 clinical trial for Hodgkin's lymphoma is on-going. • Clinical studies are planned for several types of cancer. 							

Infectious diseases

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
CS-8958	laninamivir	Inhalant	Neuraminidase inhibitor	Influenza, 1) Treatment, 2) Prophylactic	Daiichi Sankyo	US/EU JP	P1 1) Approved, 2) P3
<ul style="list-style-type: none"> CS-8958 is a long-acting neuraminidase inhibitor that is expected to be used as single administration for treatment and once a week for prophylaxis. Licensing activity with Biota in the US and EU, development by Daiichi Sankyo in Japan CS-8958 is under development as an inhalant that will act directly on the pulmonary and tracheal sites of infection. [JP] Approved for the flu treatment: Sep-2010. Brand name: Inavir 							

Bone/Joint diseases

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
AMG 162	denosumab	Injection	Anti-RANKL antibody	1) Bone metastases of cancer 2) Osteoporosis 3) Breast cancer adjuvant 4) Rheumatoid arthritis	Amgen	JP	1) Application 2,3) P3 4)P2
<ul style="list-style-type: none"> Denosumab is a fully human monoclonal antibody that specifically targets the receptor activator of nuclear factor kappa B ligand (RANKL), a key mediator of the resorptive phase of bone remodeling. July, 2007 In-licensed from Amgen P3 : Osteoporosis, Breast cancer adjuvant, P2: Rheumatoid arthritis Application: Bone metastases of cancer in Aug-2010 							

Immunological allergic diseases

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
SUN 13834	-	Oral	Chymase inhibitor	Atopic Dermatitis	Daiichi Sankyo	US	P2
<ul style="list-style-type: none"> Inhibiting chymase, one of endogenous proteases, which is released from mast cells and involves allergic reaction. Expected to be an oral anti-atopic dermatitis drug with a novel mechanism of action. 							

Others

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
KMD-3213	silodosin	Oral	Selective alpha 1A blocker	Treatment of dysuria associated with benign prostatic hyperplasia	Kissei	China	Application
<ul style="list-style-type: none"> • An alpha1A blocker which effectively reduces urinary tract resistance and improves dysuria associated with benign prostatic hyperplasia. • Reduces cardiovascular side effects due to its alpha1A selectivity. • Silodosin is marketed in Japan as brand name of UR1EF by Daiichi Sankyo and Kissei. • Development by Daiichi Sankyo in China • Application: Dec-2008 							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
SUN 11031	human ghrelin	Injection	Appetite stimulation/ Increase gastric motility	Cachexia Anorexia Nervosa	Daiichi Sankyo (Asubio Pharma)	US/EU JP	P2 P3
<ul style="list-style-type: none"> • Ghrelin is an endogenous peptide known as one-and-only peripheral appetite stimulator among all hormones discovered the relationship with feeding behavior up to now. In addition to it, ghrelin is a potent stimulator of growth hormone release. • P2 study for cahexia in US/EU, and P3 study for anorexia nervosa in Japan are on-going. 							

Development Code Number	Generic Name	Dosage Form	Class	Indication	Origin	Region	Stage
DD-723-B	perflubutane	Injection	Ultrasound contrast agent	Contrast for prostatic tumor Contrast for mammary tumor	GEHC	JP	P3 P3
<ul style="list-style-type: none"> • DD-723-B is marketed in Japan as a brand name of Sonazoid for injection. 							

1. Summary of Consolidated Income Statement (FY2009)

JPY Bn	Q1			Q2			Q3			Q4			FY2009			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	227.1	+11.5%	100%	243.4	+20.2%	100%	255.1	+15.3%	100%	226.4	+5.6%	100%	952.1	110.0	+13.1%
Cost of sales	28%	62.5	+28.5%	31%	74.7	+52.5%	30%	75.4	+41.9%	29%	65.4	+2.8%	29%	278.0	63.6	+29.7%
Gross Profit	72%	164.6	+6.1%	69%	168.7	+9.8%	70%	179.7	+6.8%	71%	161.1	+6.7%	71%	674.1	46.3	+7.4%
SG&A expenses	61%	137.8	+19.8%	59%	144.6	+9.6%	55%	140.5	+6.6%	69%	155.6	-2.8%	61%	578.6	39.7	+7.4%
R&D expenses	20%	45.1	+22.2%	20%	49.0	+7.9%	19%	47.6	+1.6%	24%	55.1	-0.5%	21%	196.8	12.3	+6.6%
Other expenses	41%	92.7	+18.6%	39%	95.6	+10.5%	36%	92.9	+9.4%	44%	100.5	-4.0%	40%	381.8	27.4	+7.7%
Operating Income	12%	26.8	-33.1%	10%	24.1	+11.5%	15%	39.2	+7.6%	2%	5.4	-	10%	95.5	6.6	+7.5%
Non-operating income / expenses		-19.6			21.0			-0.8			7.0			7.6	41.3	
Non-operating income		3.9			10.9			4.3			9.1			28.2	15.9	
Non-operating expenses		23.5			-10.1			5.1			2.1			20.6	-25.4	
Ordinary Income	3%	7.2	-82.5%	19%	45.1	+140.0%	15%	38.4	+14.4%	6%	12.5	-	11%	103.1	47.9	+86.9%
Extraordinary income / losses		1.5			-0.1			-1.1			-6.1			-5.7	357.7	
Extraordinary income		2.1			0.2			1.5			2.1			5.9	2.1	
Extraordinary losses		0.7			0.3			2.5			8.1			11.6	-355.6	
Income before income taxes and minority interests	4%	8.6	-78.2%	18%	45.0	+164.3%	15%	37.3	-	3%	6.4	-	10%	97.4	405.6	-
Income taxes / minority interests		15.1			19.9			16.8			3.8			55.5	148.3	
Income taxes		24.0			12.8			16.0			-2.7			50.0	129.2	
Minority interests		-8.9			7.1			0.7			6.5			5.5	19.1	
Net Income	-3%	-6.4	-	10%	25.1	+182.7%	8%	20.6	-	1%	2.6	-96.8%	4%	41.9	257.4	-
Effective tax rate		278%			28%			43%			-			51%		
Overseas sales ratio results		48%			50%			47%			57%			51%		

2. Currency Rate (FY2009)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2009
	Results	Results	Results	Results	Results YoY
USD/JPY (average)	97.33	95.50	93.57	92.86	92.86 -7.68
EUR/JPY (average)	132.58	133.16	133.00	131.16	131.16 -12.33
INR/JPY (average)	1.89	1.95	1.95	1.95	1.95 -0.05

3. Segment Information (FY2009)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2009			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	197.4	-3.1%	100%	207.0	+2.2%	100%	219.1	-1.0%	100%	181.9	+3.4%	100%	805.5	1.9	+0.2%
Cost of sales	23%	45.4	-6.7%	26%	54.3	+10.9%	25%	55.6	+4.6%	26%	47.3	+14.6%	25%	202.6	10.5	+5.5%
Gross Profit	77%	152.0	-2.0%	74%	152.7	-0.6%	75%	163.5	-2.8%	74%	134.6	+0.0%	75%	602.8	-8.6	-1.4%
SG&A expenses	62%	122.0	+6.0%	61%	126.5	-4.2%	57%	124.3	-1.5%	74%	134.8	+3.3%	63%	507.6	3.8	+0.8%
R&D expenses	22%	43.0	+16.5%	23%	46.7	+2.8%	21%	45.2	-3.5%	28%	51.6	+12.4%	23%	186.5	11.4	+6.5%
Other expenses	40%	79.0	+1.1%	39%	79.8	-7.8%	36%	79.1	-0.3%	46%	83.2	-1.7%	40%	321.1	-7.7	-2.3%
Operating Income	15%	30.0	-24.9%	13%	26.2	+21.3%	18%	39.1	-6.7%	0%	-0.2	-	12%	95.2	-12.4	-11.5%
Non-operating income		2.9			2.0			1.8			0.4			7.1	-3.8	
Non-operating expenses		0.8			1.8			2.2			1.4			6.1	-13.9	
Ordinary Income	16%	32.2	-21.3%	13%	26.4	+40.5%	18%	38.7	-0.8%	-1%	-1.1	-	12%	96.1	-2.2	-2.3%
Extraordinary income		2.1			0.2			1.5			0.8			4.6	0.9	
Extraordinary losses		0.7			0.3			2.5			8.1			11.6	-4.0	
Income before income taxes and minority interests	17%	33.6	-15.0%	13%	26.3	+54.4%	17%	37.7	+0.5%	-5%	-8.5	-	11%	89.1	2.7	+3.2%
Income taxes		23.6			13.1			17.7			-0.2			54.3	17.8	
Minority interests																
Net Income	5%	10.0	-60.1%	6%	13.2	+48.0%	9%	20.0	-27.9%	-5%	-8.3	-	4%	34.8	-15.1	-30.2%
Ranbaxy Group	Q1			Q2			Q3			Q4			FY2009			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	29.7		100%	36.4		100%	36.0		100%	44.5	+15.1%	100%	146.7	108.0	
Cost of sales	58%	17.1		56%	20.4		55%	19.8		41%	18.1	-12.0%	51%	75.4	54.9	
Gross Profit	42%	12.6		44%	16.0		45%	16.2		59%	26.4	+45.8%	49%	71.2	53.1	
SG&A expenses	48%	14.4		46%	16.6		41%	14.6		43%	19.3	+10.0%	44%	64.9	47.4	
R&D expenses	7%	2.1		6%	2.3		7%	2.4		8%	3.5	+35.7%	7%	10.3	7.7	
Other expenses	41%	12.3		39%	14.3		34%	12.2		36%	15.8	+5.6%	37%	54.6	39.6	
Operating Income	-6%	-1.8		-2%	-0.6		4%	1.6		16%	7.1	+1119.4%	4%	6.3	5.7	
Non-operating income		1.0			9.0			2.5			8.7			21.1	19.7	
Non-operating expenses		22.7			-11.9			2.9			0.7			14.5	-11.5	
Ordinary Income	-79%	-23.5		56%	20.2		3%	1.2		34%	15.1	-	9%	13.0	36.9	
Extraordinary income		0.0			0.0			0.0			1.3			1.3	1.2	
Extraordinary losses								0.0			0.1			0.1	-0.2	
Income before income taxes and minority interests	-79%	-23.5		56%	20.2		3%	1.1		37%	16.4	-	10%	14.2	38.3	
Income taxes		-6.6			6.0			1.3			9.2			9.8	17.7	
Minority interests		0.0			0.0			0.1			0.1			0.2	0.1	
Net Income	-57%	-16.9		39%	14.2		-1%	-0.2		16%	7.1	-	3%	4.2	20.4	
Inter-segment Transactions																
Net sales																
Cost of sales																
Gross Profit																
SG&A expenses		1.5			1.5			1.5			1.5			6.0		
R&D expenses																
Other expenses		1.5			1.5			1.5			1.5			6.0		
Operating Income		-1.5			-1.5			-1.5			-1.5			-6.0		
Non-operating income																
Non-operating expenses																
Ordinary Income		-1.5			-1.5			-1.5			-1.5			-6.0		
Extraordinary income																
Extraordinary losses																
Income before income taxes and minority interests		-1.5			-1.5			-1.5			-1.5			-6.0		
Income taxes		7.0			-6.4			-3.0			-11.8			-14.1		
Minority interests		-8.9			7.1			0.7			6.5			5.3		
Net Income		0.5			-2.3			0.8			3.8			2.8		

4. Sales by Business Units (FY2009)

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Consolidated Net Sales	227.1	11.5%	243.4	20.2%	255.1	15.3%	226.4	5.6%	952.1	13.1%
Japan Company (domestic sales)	104.6	3.7%	104.8	5.3%	118.4	-1.4%	84.5	-1.9%	412.3	1.4%
Olmotec	19.0	22.1%	19.8	26.1%	22.2	18.8%	16.2	12.5%	77.2	20.0%
Calblock	3.5	14.5%	3.5	18.9%	3.8	12.5%	2.9	4.7%	13.7	12.8%
Loxonin	11.2	33.0%	12.5	19.7%	13.3	16.0%	9.9	19.4%	47.0	21.4%
Cravit	9.5	-6.8%	11.9	26.7%	10.8	-21.0%	11.4	17.5%	43.6	1.5%
Mevalotin	12.4	-8.3%	12.4	-5.0%	12.8	-9.1%	8.5	-14.7%	46.2	-8.9%
Artist	6.0	6.3%	5.9	11.3%	6.4	6.0%	5.0	1.9%	23.3	6.5%
Omnipaque	7.1	-2.0%	7.5	3.4%	7.1	-10.8%	5.5	-4.8%	27.3	-3.7%
Urief	2.2	26.6%	2.2	26.1%	2.6	19.3%	2.0	-9.9%	9.0	14.3%
Vaccines	1.3	235.0%	1.9	40.4%	8.6	22.9%	1.3	151.5%	13.1	41.0%
Daiichi Sankyo Healthcare (OTC)	9.5	-6.9%	13.5	-2.1%	12.1	-8.2%	8.6	-14.1%	43.7	-7.4%
Daiichi Sankyo, Inc. (US)	33.0	-11.2%	33.5	5.6%	34.4	5.8%	32.1	15.2%	133.0	2.9%
Olmesartan	25.1	1.5%	25.4	3.5%	26.4	5.9%	24.9	13.6%	101.7	5.9%
Benicar/Benicar HCT	22.1	-5.6%	22.2	0.5%	22.7	2.0%	21.9	11.7%	88.9	1.8%
Azor	3.0	121.5%	3.2	30.9%	3.6	38.6%	2.9	29.7%	12.8	47.2%
Welchol	6.9	7.0%	6.5	6.6%	7.3	10.2%	6.8	28.2%	27.5	12.4%
Effient (alliance revenue)	-	-	1.0	-	0.2	-	-1.1	-	0.1	-
Luitpold Pharmaceuticals, Inc. (US)	13.4	-1.1%	13.5	-0.4%	12.6	-6.4%	12.7	18.9%	52.1	1.9%
Venofer	8.0	-3.9%	8.1	-4.6%	8.0	-4.1%	8.0	17.0%	32.2	0.3%
Daiichi Sankyo Europe GmbH	17.3	14.1%	18.4	-0.4%	19.1	6.1%	20.4	9.7%	75.2	7.1%
Olmesartan	9.2	10.7%	11.2	7.9%	12.4	17.9%	13.5	28.3%	46.3	16.5%
Olmotec/Olmotec Plus	8.3	-0.2%	10.0	-3.7%	10.2	12.1%	11.4	17.7%	39.9	6.5%
Sevikar	0.9	-	1.2	-	2.2	56.5%	2.0	156.5%	6.3	189.3%
Asia, South and Central America (ASCA)	5.3	0.5%	6.3	7.1%	6.6	11.7%	7.7	27.5%	25.8	12.1%
Daiichi Sankyo Pharmaceutical (Beijing)	1.0	-4.3%	1.1	7.6%	1.1	3.1%	0.9	1.4%	4.1	2.0%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.1	48.0%	1.3	40.2%	1.4	35.2%	1.5	34.0%	5.3	38.4%
Daiichi Sankyo Taiwan	0.9	-8.6%	0.8	-14.9%	0.7	-14.4%	0.7	-4.5%	3.1	-10.7%
Daiichi Sankyo Korea	0.8	-15.6%	0.9	-2.1%	0.9	56.8%	0.9	38.9%	3.4	13.7%
Daiichi Sankyo (Thailand)	0.2	-0.9%	0.2	-0.4%	0.2	4.2%	0.3	27.4%	0.9	7.7%
Daiichi Sankyo Brasil Farmacêutica	0.8	-25.5%	1.0	-12.7%	1.3	-7.2%	1.6	18.4%	4.7	-5.2%
Daiichi Sankyo Venezuela	0.7	35.3%	0.9	45.0%	0.8	20.7%	1.7	76.3%	4.1	47.9%
Ranbaxy Laboratories Limited	29.7	-	36.4	-	36.0	-	44.4	14.9%	146.6	-
Others	14.4	-33.2%	17.1	-13.6%	15.9	-12.3%	16.0	-3.0%	63.4	-16.5%
Levofloxacin export, royalty, etc	8.5	-37.8%	9.6	-21.6%	9.2	-10.3%	8.6	-22.1%	35.9	-24.0%
Effient alliance revenue (Europe)	0.0	-	0.0	-	0.1	-	0.4	-	0.5	-

[Reference] Sales in Local Currency (FY2009)

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
Daiichi Sankyo, Inc. (US)	339	-4.6%	357	21.7%	382	13.4%	354	18.0%	1,433	11.4%
Olmesartan	258	9.0%	271	18.9%	293	13.9%	274	16.9%	1,095	14.6%
Benicar/Benicar HCT	227	1.4%	237	15.6%	253	9.7%	242	14.8%	958	10.2%
Azor	31	138.0%	34	49.3%	40	50.9%	32	35.4%	138	59.4%
Welchol	71	14.9%	69	22.8%	81	18.7%	75	31.4%	296	21.7%
Effient (alliance revenue)	-	-	10	-	2	-	-11	-	1	-
USD Mn										
Luitpold Pharmaceuticals, Inc. (US)	137	6.2%	144	14.5%	140	1.1%	140	21.4%	561	10.3%
Venofer	82	3.2%	87	9.6%	89	3.3%	89	19.8%	346	8.6%
EUR Mn										
Daiichi Sankyo Europe GmbH	131	40.6%	138	20.8%	144	5.9%	161	9.8%	574	17.1%
Olmesartan	69	36.4%	83	30.9%	93	18.4%	106	28.1%	353	27.5%
Olmetec/Olmetec Plus	63	23.0%	74	16.7%	77	10.6%	90	17.2%	304	16.5%
Sevikar	7	-	9	-	16	77.6%	16	166.6%	48	216.5%
INR Bn										
Ranbaxy Laboratories Limited	16	-	18	-	18	-	23	17.9%	75	-

5. Sales of Global Products (FY2009)

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Olmesartan	56.0	10.5%	59.4	10.2%	64.7	12.3%	58.3	19.0%	238.3	12.9%
Olmetec (JPN)	19.0	22.1%	19.8	26.1%	22.2	18.8%	16.2	12.5%	77.2	20.0%
Benicar/Benicar HCT (US)	22.1	-5.6%	22.2	0.5%	22.7	2.0%	21.9	11.7%	88.9	1.8%
Azor (US)	3.0	121.5%	3.2	30.9%	3.6	38.6%	2.9	29.7%	12.8	47.2%
Olmetec/Olmetec Plus (EU)	8.3	-0.2%	10.0	-3.7%	10.2	12.1%	11.4	17.7%	39.9	6.5%
Sevikar (EU)	0.9	-	1.2	-	2.2	56.5%	2.0	156.5%	6.3	189.3%
Other subsidiaries, export, etc	2.6	29.9%	3.1	-7.8%	3.7	6.2%	3.7	71.4%	13.1	19.2%
Levofloxacin	19.8	-23.2%	23.5	-0.3%	22.1	-14.2%	21.8	-3.5%	87.2	-10.7%
Cravit (JPN)	9.5	-6.8%	11.9	26.7%	10.8	-21.0%	11.4	17.5%	43.6	1.5%
Export, royalty, etc	8.5	-37.8%	9.6	-21.6%	9.2	-10.3%	8.6	-22.1%	35.9	-24.0%
Other subsidiaries	1.8	-6.4%	2.0	2.9%	2.1	14.7%	1.8	-2.2%	7.7	2.2%
Pravastatin	14.7	-8.5%	15.0	-5.2%	14.8	-10.8%	10.5	-14.9%	55.0	-9.6%
Mevalotin (JPN)	12.4	-8.3%	12.4	-5.0%	12.8	-9.1%	8.5	-14.7%	46.2	-8.9%
Other subsidiaries, export, etc	2.3	-10.0%	2.6	-6.5%	2.0	-20.2%	2.0	-15.7%	8.8	-12.8%
Prasugrel (alliance revenue)	0.0	-	1.0	-	0.3	-	-0.7	-	0.5	-
Effient alliance revenue (US)	-	-	1.0	-	0.2	-	-1.1	-	0.1	-
Effient alliance revenue (EU)	0.0	-	0.0	-	0.1	-	0.4	-	0.5	-

Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance
Japan Company (domestic sales)					
Olmotec	olmesartan	antihypertensive	2004	Daiichi Sankyo	Kowa
Rezaltas	olmesartan / azelnidipine	antihypertensive	2010	Daiichi Sankyo	
Calblock	azelnidipine	antihypertensive	2003	Ube Industries	
Loxonin	loxoprofen	analgesic and anti-inflammatory	1986	Daiichi Sankyo	
Loxonin Poultice			2006	Lead Chemical	
Loxonin Tape			2008	Lead Chemical	
Loxonin Gel			2010	Daiichi Sankyo	
Cravit			levofloxacin	antibacterial	
Mevalotin	pravastatin	antihyperlipidemic	1989	Daiichi Sankyo	
Artist	carvedilol	antihypertensive	1993	Roche	
Omnipaque	iohexol	contrast medium	1987	GE Healthcare	
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei
Inavir	laninamivir	anti-influenza	2010	Daiichi Sankyo	
Daiichi Sankyo, Inc. (US)					
Olmecartan	olmesartan olmesartan / hydrochlorothiazide olmesartan / amlodipine olmesartan / amlodipine / hydrochlorothiazide	antihypertensive	2002	Daiichi Sankyo	
Benicar			2003		
Benicar HCT			2007		
Azor			2010		
Tribenzor					
Welchol	colesevelam	antihyperlipidemic / type 2 diabetes	2000	Genzyme	
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly
Luitpold Pharmaceuticals, Inc. (US)					
Venofer	iron sucrose injection	iron deficiency anemia	2000	Vifor Pharma	Fresenius
Daiichi Sankyo Europe GmbH					
Olmecartan	olmesartan olmesartan / hydrochlorothiazide olmesartan / amlodipine olmesartan / amlodipine / hydrochlorothiazide	antihypertensive	2002	Daiichi Sankyo	Menarini Pfizer Nycomed
Olmotec			2005		
Olmotec Plus			2009		
Sevikar			2010		
Sevikar HCT					
Efient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly